Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Pipeline Updates
Summary
Terns Pharmaceuticals, Inc. reported its financial results for the second quarter of 2025, showing a cash runway into 2028. The company highlighted strong enrollment in the Phase 1 trial of TERN-701 for chronic myeloid leukemia, with efficacy and safety data expected in Q4 2025. The Phase 2 trial of TERN-601 for obesity completed enrollment, with 12-week data anticipated in early Q4 2025. The company plans to focus on its oncology program and partner its metabolic assets, without further investment in metabolic disease beyond 2025.
Profitelligence Alerts
Get alerts for TERN
Be first to know when Terns Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic candidates targeting liver disease and oncology. Its primary function is to advance its pipeline of clinical and preclinical drug candidates that address significant unmet medical needs. One of the company's main focuses is on non-alcoholic steatohepatitis (NASH), a progressive liver disease. Through innovative approaches, Terns Pharmaceuticals explores various mechanisms to treat NASH, including small molecules designed to reduce liver inflammation and fibrosis. Beyond liver disease, the company is expanding its platform to include oncology, diversifying its impact in the healthcare industry. As a key player in the biopharmaceutical sector, Terns Pharmaceuticals Inc. contributes to the growing landscape of targeted therapies. With a dedicated emphasis on research and development, the company plays an essential role in pushing the boundaries of treatment options, potentially transforming the management of chronic liver diseases and cancer.
Official SEC Documents
Advertisement